Array's Melanoma Drug Promising in Phase 2 Study

Array BioPharma, Inc.

A report from Melanoma News Today that Array BioPharma Inc. recently presented the latest results of its Phase 2 clinical trial of binimetinib in patients with advanced NRAS mutant melanoma, at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.